Numerous trials are exploring immunotherapy combination approaches in advanced cancers with a backbone of PD‐1/PD‐L1/CTLA4 inhibition in conjunction with Treg cell focused agents including those targeting the Inducible T cell Co‐Stimulator (ICOS) receptor (NCT02723955), and GITR (NCT03126110). Here, CTLA4 is linked to cancer.